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Abstract
Vascularization of the vertebrate brain takes place during embryonic development from a preformed perineural
vascular plexus. As a consequence of the intimate contact with neuroectodermal cells the vessels, which are enter-
ing the brain exclusively via sprouting angiogenesis, acquire and maintain unique barrier properties known as the
blood-brain barrier (BBB). The endothelial BBB depends upon the close association of endothelial cells with peri-
cytes, astrocytes, neurons and microglia, which are summarized in the term neuro-vascular unit. Although it is
known since decades that the CNS tissue provides the cues for BBB induction and differentiation in endothelial
cells, the molecular mechanism remained obscure.
Only recently, the canonical Wnt/b-catenin pathway and the Wnt7a/7b growth factors have been implicated in
brain angiogenesis on the one hand and in BBB induction on the other. This breakthrough in understanding the
differentiation of the brain vasculature prompted us to review these findings embedded in the emerging concepts
of Wnt signaling in the vasculature. In particular, interactions with other pathways that are crucial for vascular
development such as VEGF, Notch, angiopoietins and Sonic hedgehog are discussed. Finally, we considered the
potential role of the Wnt pathway in vascular brain pathologies in which BBB function is hampered, as for example
in glioma, stroke and Alzheimer’s disease.
Introduction
In vertebrate ontogenesis, blood vessels arise through
differentiation of mesodermal hemangioblasts into
endothelial cells (ECs), which assemble into so-called
blood islands of the extraembryonic yolk sac and into
the aortic primordia of the embryo proper [1]. The first
ECs form a primitive vascular network in a process
defined as vasculogenesis with subsequent growth and
remodeling of preformed vessels known as angiogenesis
[2]. In fact, most organs are vascularized by initial vas-
culogenesis subsequently followed by angiogenic
sprouting.
The central nervous system (CNS) however, is exclu-
sively vascularized by angiogenesis starting at embryonic
day 9 in rodents from the perineural vascular plexus
(PVP), covering the entire surface of the neural tube [2].
In the adult, vessels will supply the brain with oxygen
and glucose and they assure that metabolic end pro-
ducts are removed to maintain tissue homeostasis. This
is of upmost importance as the function of neurons and
glia depends on ion-based concentration gradients
established in brain fluids, i.e. cerebrospinal fluid (CSF),
providing a unique milieu for electrical nerve cell com-
munication. Consequently, the brain is protected from
the free diffusion between blood plasma and the intersti-
tium by a vascular blood-brain barrier (BBB) in order to
maintain CSF homeostasis.
The mature BBB consists of a complex cellular system
in which capillaries are regularly covered by a high
number of pericytes embedded in a common basal
membrane and by astrocytic endfeet. The circumference
of brain capillaries is lined by a single endothelial cell
connected with itself and neighboring endothelial cells
by complex tight junctions (TJs), intermingled with
non-occluding adherens junctions (AJs) [3]. AJs are
formed by the endothelial specific integral membrane
protein VE-cadherin, which is linked to the cytoskeleton
via catenins. Endothelial expression and localization of
b-catenin, g-catenin and p120
ctn have been described to
be crucial for the functional state of AJs including those
of brain ECs (for review see [4]) (Figure 1). TJs in the
CNS of mice and men are formed by occludin, as well
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proteins [5]. In particular the endothelial specific clau-
din-5, which is also present in non-brain ECs, and clau-
din-3 were shown to localizet oe n d o t h e l i a lT J si nt h e
CNS [6]. Moreover, claudin-1 and claudin-12 are
described in brain ECs but their role is still unclear [6,7]
(Figure 1). The complex TJs between brain ECs establish
a high electrical resistance across the endothelial barrier
(about 2000Ω ×c m
2) that is the hallmark of the BBB
[8].
As ECs start to form an elaborate network of TJs dur-
ing BBB differentiation, they start also to express selec-
tive transporters, such as glucose transporter type1
(Glut-1), members of the ATP binding cassette (ABC)
transporter family (ABCB1/P-glycoprotein/MDR1 and
ABCG2), and enzymes which together establish the
complex phenotype of the BBB (for review see [9]).
In contrast to the genes, which become upregulated in
brain endothelia during BBB maturation, the panen-
dothelial cell antigen MECA-32 (also known as plasma-
lemma vesicle associated protein 1, Plvap1) becomes
specifically down regulated [10]. As a consequence, the
MECA-32 antigen is absent on the mature cerebral
endothelium, whereas it remains present on vessels
outside the CNS and on capillaries within the circum-
ventricular organs (CVOs) (Figure 1).
Driven by the question what makes endothelial cells
grow into the neuroectoderm, in the 1980s Werner
Risau
✝ hypothesized that soluble factors produced by the
brain and recognized by specific receptors on ECs of the
PVP are responsible for brain angiogenesis. Although
the initial candidates aFGF/bFGF were potent inducers
of EC proliferation in vitro and of angiogenesis in vivo
[11-13], their expression did not match the spatio-tem-
poral pattern of brain angiogenesis [14-16]. When the
vascular endothelial growth factor (VEGF) was identified
in the brain ventricular layer, it became the most pro-
mising candidate factor specifically stimulating endothe-
lial proliferation and sprouting via its high affinity
receptors VEGF receptor 1 (VEGFR1, flt-1) and VEGF
receptor 2 (VEGFR2, flk-1/KDR) (summarized in [17]).
Although VEGF seems to provide the most important
angiogenic stimulus also in the brain, other growth fac-
tor-receptor systems have been implicated in vascular
development in the CNS. In particular, angiopoietin-1
and -2 (Ang-1, Ang-2) and their common receptor Tie2
have been shown to be involved in vascular sprouting
and remodeling, namely in the adhesion to the ECM
Figure 1 Schematic junctional organization and b-catenin signaling in CNS ECs: comparison of brain and retina. A In the brain and
spinal cord mainly Wnt7a and Wnt7b growth factors act on an uncharacterized Fzd-LRP receptor complex to elicit b-catenin target gene
transcription. The positively regulated target genes identified so far are the TJ protein claudin-3, Glut-1 and ABCB1/MDR1. Conversely, the
expression of Meca-32/Plvap becomes suppressed by b-catenin transcription via an unknown mechanism. B in the retina Norrin is the
predominant ligand activating b-catenin signaling downstream of the Fzd4-LRP5-TSPAN12 receptor complex. So far only the repression of Meca-
32/Plvap was identified as target of this signaling. To date the effect of Norrin signaling on claudin-3, Glut-1 or other barrier-related genes is not
know. See the grey supported area and arrows for the “canonical” Wnt pathway.
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Furthermore, the platelet derived growth factor B
(PDGF-BB) has been shown to be important for pericyte
recruitment in general and interestingly, mice deficient
for PDGF-BB show a complete lack of pericyte invest-
ment of brain vessels [19].
One major drawback for understanding brain angio-
genesis is that these mechanisms also apply outside the
CNS. Therefore, it seems unlikely that they are specifi-
cally involved in BBB differentiation creating highly spe-
cialized ECs.
The motivation for this review is drawn from recent
reports indicating that in particular the Wnt ligands
Wnt 7a/b, signaling via the Wnt/b-catenin pathway,
could act as CNS-specific morphogens regulating parti-
cularly steps of angiogenesis and vascular differentiation
[20-22].
The players in the Wnt pathway
Wnt signaling regulates various biological processes on a
cellular level such as proliferation, apoptosis, polarity
and differentiation as well as pluripotency of stem cells.
These functions have consequences on a tissue or organ
level, influencing axis determination, segmentation as
well as branching of tubular structures [23]. Wnts are a
family of 19 secreted glycoproteins that primarily signal
through seven-pass transmembrane receptors of the
frizzled family (Fzd) [23]. Wnt proteins undergo exten-
sive post-translational modification, such as glycosyla-
tion and palmitoylation, which influence solubility and
diffusability of the proteins, and their accumulation in
the extracellular matrix [24,25]. The term “Wnt signal-
ing” comprises at least three related pathways (see Fig-
ure 2), of which the best-characterized one is the
“canonical” or b-catenin (armadillo in Drosophila sp.)
mediated pathway, as opposed to two “non-canonical”
or b-catenin-independent pathways (see below). Canoni-
cal Wnt signaling involves binding of Wnt growth fac-
tors to the cystein-rich domain (CRD) of Fzd, which
forms a receptor complex with the co-receptor LDL-
receptor related protein 5/6 (LRP-5/-6, arrow in Droso-
phila sp.). In the absence of Wnt ligands the degrada-
tion complex, formed by Axin, glycogen syntase kinase
Figure 2 Scheme of known Wnt pathways. A Canonical Wnt/b-catenin pathway. In the “off-state” no Wnt proteins are present or are inhibited
by factors like WIF, sFRPs and Dkk. Cytosolic b-catenin is targeted to proteolytic degradation through phosphorylation by the APC-Axin-GSK3b-
CK1á complex and ubiquitination by the bTrCP-dependent E3 ubiquitin ligase. In the “on-state” stimulation of Fzd receptors and their co-
receptors Lrp5/6 by Wnt ligands, leads to recruitment of Dvl and Axin to Fzd, thereby inhibiting the degradation complex. Consequently, b-
catenin accumulates in the cytoplasm and enters the nucleus, activating target gene transcription through association with Lef1/TCF. B Non-
canonical Wnt/Ca
2+ pathway. Interaction of non-canonical Wnt ligands with Fzd receptors can lead to G-Protein mediated phosphorylation of
Dsh, thereby activating PLC and increasing intracellular calcium levels. These will activate CAMKII and PKC, as well as the transcription factor
NFAT. Additionally, Fzd receptors in association with Kny, Ror2 or Ryk receptors can activate JNK, promoting target gene expression through AP-
1. C Non-canonical Wnt/PCP pathway. This pathway is characterized by an asymmetric distribution of Fzds, the cadherin Flamingo and VANGL2,
resulting in cell polarization. Wnt signaling promoted by either Wnt or an interaction of Fzd with VANGL2 activates RhoA/B, Cdc42 or Rac1. Dsh
activates Rac1, while RhoA/B and Cdc42 need the participation of Daam1 downstream of Dsh. Rac1 can also activate JNK, resulting in the NFAT
pathway. All three down stream pathways are key players in cytoskeletal rearrangement and cellular polarity. The signaling of the Flamingo/Fzd
interaction is still obscure.
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kinase 1a (CK1a) and adenomatous poliposis coli
(APC), accomplishes the N-terminal phosphorylation of
b-catenin at Ser45 (by CK1-a) and subsequently, at
Thr41, Ser37, and Ser33 (by GSK-3b) [26]. Phosphory-
lated b-catenin becomes ubiquitinated by b TrCP (Slimb
in Drosophila sp.) and degraded in the proteasome [27].
Wnt ligand binding leads by incompletely understood
mechanisms to the activation of the cytoplasmic protein
disheveld (Dvl), and subsequently to the recruitment of
Axin to the LRP co-receptor, which results in the decay
of the degradation complex, hence to the stabilization of
b-catenin in the cytoplasm. Upon translocation to the
nucleus, b-catenin displaces the transcriptional repressor
groucho from the interaction with members of the lym-
p h o i de n h a n c e rf a c t o r( L e f ) / T - c e l lf a c t o r( T C F )t r a n -
scriptional activators to start target gene transcription
(Figure 2A) [28,29].
The non-canonical pathways, which are defined by the
independence of b-catenin as a central signaling molecule,
are an assembly of by now loosely separable pathways.
Wnt5a, Wnt4 and Wnt11 are considered to be prototype
non-canonical Wnts, which do not induce axis duplication
in Xenopus. Instead, non-canonical Wnts may induce Ca
2
+ release and activation of the protein kinase C (PKC) or
Ca
2+/calmodulin-dependent protein kinase (CamkII), both
summarized as the Ca
2+-pathway (Figure 2B). Alterna-
tively, non-canonical Wnts can activate Rac, Cdc42,
RhoA/B and downstream c-Jun N-terminal kinase (JNK)
or RAB4, known as the planar cell polarity pathway (PCP).
The latter has been identified in Drosophila, but is also
present in vertebrate organisms and plays a crucial role in
cellular convergence and extension movements during
organogenesis [30]. PCP can also be activated/modulated
by non-Wnt related, membrane bound Fzd ligands such
as Flamingo, a member of the adhesion-G-protein coupled
receptor (GPCR) family (mammalian orthologs CELSR1,
CELSR2, CELSR3), and strabismus/Van Gogh (for review
see (Figure 2C) [31]).
Moreover, secreted antagonists, including Dickkopf
homologs (Dkk1-4), secreted frizzled-related protein
families (sFRPs, 1-5), and atypical Wnt receptors, such as
the receptor-like tyrosine kinase (Ryk) and receptor tyro-
sine kinase-like orphan receptors (Ror), can regulate the
Wnt signaling output (see Figure 2) [32]. Furthermore,
Fzd ligands, which are structurally unrelated to Wnts,
such as the Norrie disease pseudoglioma protein (Nrp,
Norrin), have been described to activate b-catenin tran-
scriptional activity particularly in the vascular system and
are discussed in detail in the following chapters [33].
Wnt pathway in vascular beds of the central
nervous system
So far the Wnt/b-catenin pathway has been reported to
be involved in various aspects of EC biology and in
angiogenesis, such as proliferation and vessel assembly.
The reader is referred to the following review articles
comprehensively summarizing the general role of the
Wnt pathway during developmental vasculo- and angio-
genesis (for review see [34-36]).
Vessels in the brain and spinal cord
Recently, it could be demonstrated that the combined
inactivation of Wnt7a and Wnt7b leads to severely
defective angiogenesis in the central nervous system
(CNS) [20,22]. Wnt7a and b are expressed with overlap-
ping domains in the presumptive forebrain and ventral
neural tube. EC-specific deletion of b-catenin phenoco-
pies the angiogenic defects in the CNS, suggesting that
Wnt7a and 7b promote CNS vascularization by activat-
ing canonical Wnt signaling [20,22]. The endothelial
receptors involved in CNS-specific vascular Wnt signal-
ing remain to be identified. Notably, EC-specific deletion
of b-catenin also causes angiogenic defects in the non-
CNS vasculature, including vascular patterning defects
in the embryo proper and placenta [37]. Additionally, b-
catenin KO mice lack regular heart valve development
due to abrogated endocardial Wnt signaling [38], leading
to earlier embryonic lethality compared to the Wnt7a/b
double KO [20,22]. As a consequence, canonical Wnt/b-
catenin signaling may be involved in regulating vascular
morphogenesis throughout the organism, but selective
Wnt ligands and/or Fzd receptors may provide organ-
specific angiogenic functions.
It is obvious that, when brain angiogenesis starts,
endothelial cells get in contact with various neuroecto-
dermal cells like neuroblasts and various glial cells and/
or their precursors [39]. That endothelial cells do not
show a predetermination to the BBB phenotype was ele-
gantly shown by chick-quail xenografts in which vessels
of the coelimic cavity of the embryonic chick acquired
BBB characteristics when growing into the developing
transplanted quail brain [40].
Although numerous aspects of BBB development in
brain capillary ECs have been monitored and described,
the crucial question concerning the mechanism behind
the induction of this differentiation process remained to
be elucidated.
In this regard, it was of major interest whether Wnts,
in addition to their function in brain angiogenesis,
might participate also in the differentiation of the BBB
phenotype in brain ECs. Indeed, Wnt7a and Wnt7b
were also shown to induce expression of the glucose
transporter 1 (Glut1), an early marker of endothelial
BBB specialization (see Figure 1A) [20,22].
Moreover, we demonstrated in a collaborative effort
that b-catenin-TCF mediated Wnt signaling in ECs is
necessary and sufficient to induce the mature molecular
and structural properties of BBB-type endothelial TJs and
barrier maturation in vitro and in vivo [21]. Activation of
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media or dominant active b-catenin selectively induces
claudin-3 and represses Meca-32 expression, a marker for
immature brain vessels, in mouse brain ECs (MBEs) (see
Figure 2) [21]. In contrast to claudin-5, claudin-3 is predo-
minantly present in brain ECs and is specifically upregu-
lated during BBB establishment and maintenance
although the specific function of claudin-3 for BBB TJs
remains elusive [6]. Interestingly, ectopic Wnt7a expres-
sion by Nestin-Cre-mediated recombination in scattered
cells outside the CNS was sufficient to induce Glut-1
expression in non-brain ECs [22]. Similarly, viral infection
of a non-brain endothelioma cell line with dominant-
active b-catenin, was sufficient to upregulate claudin-3
and to downregulate Meca-32 [21]. These findings support
the results of chick-quail chimera experiments, suggesting
that the specificity of BBB induction in vivo is achieved by
the brain milieu, which we now know is at least partially
defined by the selective availability of Wnt ligands, rather
than by a selective receptor endowment of ECs. However,
further studies are needed to clarify this issue in detail.
Furthermore, the contribution of other Wnts than
Wnt7a/b to endothelial barrier induction in vivo remains
elusive. As Wnt7a/b are predominantly expressed in the
ventricular zone of the developing forebrain and in ventral
portions of the neural tube, other Wnt ligands such as
Wnt1, 3, 3a and 4 may take over barrier induction in dor-
sal parts of the neuroectodem [20].
Most of the brain capillaries develop BBB characteris-
tics, hence induction needs to take place in the majority
of ECs with the only exception in vessels of the CVOs
[41]. Leaky areas, lacking an endothelial BBB, are
located at strategic positions of the ventricular system,
as for example in the pituitary and the choroid plexus
where active secretion and resorption takes place,
respectively [41]. Whether in CVOs vessels are specifi-
cally devoid of Wnt signaling during angiogenesis of the
CNS has to be clarified in future investigations.
Vessels in the retina
During angiogenesis of the retina as part of the CNS,
microvessels form the blood-retina barrier (BRB), which
is structurally and functionally similar to the BBB. In
the retina, Wnt signaling has been reported to regulate
specification of stalk cells in the expanding vascular net-
work [42]. Herein the Notch-regulated ankyrin repeat
protein (Nrarp), a gene activated by Delta-like 4 (Dll4)/
Notch1 signaling in stalk cells, promotes canonical Wnt
signaling through direct interaction with Lef1 [42]. ECs
lacking Nrarp show decreased levels of Lef1 and
cyclinD1, and a reduced proliferation rate, indicating a
possible in vivo role of Wnt signaling in regulating EC
proliferation [42].
Fzd4 KO mice display retarded retinal and ear vessel
growth and inappropriate vessel pattering, delayed
hyaloid vessel regression, dead-ended aneurysm-like
capillaries, vascular leakage and abnormal corpora lutea
angiogenesis leading to infertility [43,44]. Furthermore,
the Wnt-unrelated Fzd4 ligand Norrin can activate
canonical Wnt signaling and the Norrin-deficient mouse
displays similar defects as the Fzd4 KO [45-47].
Also inactivation of the Lrp5 gene in mice leads to
delayed hyaloid vessel regression and defective migration
of retinal blood vessels [48,49]. Apparently, canonical
Wnt signaling is important for vessel regression in hya-
loid vasculature, but also for growth and stability in ret-
inal vessels. The work of Lang and co-workers suggest
that paracrine macrophage-derived Wnt7b induces vas-
cular regression of hyaloid vessels in the absence of the
survival stimulus Ang-1 [50,51]. Therefore, the specific
outcome of Wnt signaling in different vascular beds
might depend on the microenvironment and crosstalk
between different signaling pathways and survival sig-
nals, coordinating EC proliferation and apoptosis, vessel
migration and regression (Wnt, VEGF-A and Ang-1/-2).
Another interesting question is how barrier properties
are induced in retinal blood vessels, which form the
BRB. Recently, Norrin has been implicated in this func-
tion [52]. Junge and co-workers showed that Norrin sig-
nals via the receptor complex Fzd4-Lrp5, which is
specifically clustered by tetraspannnin 12 (Tspan12),
thereby enhancing b-catenin transcriptional activity (Fig-
ure 2). Interestingly, Norrin-mediated signaling downre-
gulates the expression of Meca-32, which inversely
correlates with barrier formation. Furthermore, Luh-
mann and colleagues showed that norrin-deficient mice
exhibit reduced vascular density in the cerebellum, sug-
gesting that norrin regulates vascularization also in the
cerebellum [53]. It is tempting to speculate that norrin
also directly regulates barrier properties in retinal and
cerebellar ECs as shown for Wnts in ECs of other CNS
regions [20-22].
Although by now the involvement of Wnt/b-catenin
signaling in brain angiogenesis and endothelial barrier
induction has been established, it remains to be clarified
to which extend the plethora of BBB associated genes
are directly or indirectly dependent on the Wnt path-
way. In this regard Lim and co-workers described the
up-regulation of P-glycoprotein (also know as MDR-1,
ABCB1) upon GSK3
b inhibition in immortalized human
ECs [54], supporting the idea that Wnt/
b-catenin signal-
ing regulates induction and maintenance of BBB genes
also in human ECs.
Crosstalk with other pathways in the endothelium
It is known that Wnt signaling does not regulate cell
and tissue differentiation on its own, but interacts with
other major pathways, which play a crucial role herein.
Although by now we are still scratching the surface of
the Wnt pathway in endothelial biology, it is more than
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tor tyrosine kinases (VEGF/VEGFR, FGF/FGFR), Notch,
TGFb/BMP and Sonic hedgehog (Shh) will be brought to
light by future work.
Below the currently known as well as some hypotheti-
cal interactions are discussed. The most prominent find-
ing for vascular biology was that the Wnt pathway
regulates VEGF in colon carcinoma [55]. This has also
been confirmed in human umbilical vein ECs (HUVECs)
infected with a kinase-mutant form of GSK3b,l e a d i n g
to increased b-catenin signaling and downstream VEGF
expression [56]. VEGF acts in an autocrine manner in
HUVECs, thereby activating the PI3K/Akt pathway,
leading to vascular sprouting and network formation in
matrigel in vitro.
Conversely, PI3K/Akt signaling, which is activated by
receptor tyrosine kinases (RTKs), may positively regulate
b-catenin transcriptional activity independent of Wnt-
Fzd interaction [57].
The process of vascular sprouting is regulated by
numerous signals and recent studies identified the Dll4/
Notch1 signaling axis as the key endothelial mechanism
controlling the appropriate numbers of sprouting tip
and following stalk cells (for review see [58]). Interest-
ingly, Nrarp, which is a direct target of the Notch path-
way in stalk cells, interacts with b-catenin and stabilizes
the b-catenin/Lef/TCF transcription complex, thereby
rendering b-catenin transcription active [42,58]. As in
stalk cells Jagged-1 is specifically expressed as opposed
to Dll4 in tip cells, it is tempting to speculate that
Jagged-1 could be regulated by b-catenin/TCF signaling
in ECs, as it has been described in epithelial cells of the
skin and colon [59,60].
Wnts, and in particular Wnt7a/b have recently been
implicated in vascularization of the developing neuroec-
toderm [20,22]. Similarly, Sonic hedgehog (Shh) seems to
upregulate angiogenic factors [61] and to be important
for vascularization of the neural tube in an Ang-1-
dependent manner [62]. The availability of Ang-1 was
previously discussed to be crucial for the cellular
response of hyaliod vessels to macrophage-derived
Wnt7b [50,51]. Whether Wnt7a/b or any other Wnt
ligand functionally interact with Shh to regulated brain
vascularization is still obscure. However, ventral Shh sig-
naling in the neural tube is important to maintain dorsal
b-catenin/TCF signaling on a physiological level [63].
Whether this applies also to the angiogenic blood vessel
needs to be clarified.
T h e r ei sa m p l ee v i d e n c et h a tt h eN F - B pathway and
the Wnt/b-catenin pathway interact to differentially reg-
ulate inflammation, tumor formation, metastasis and
resistance to chemotherapy in epithelial cells [64].
Apparently, GSK3b plays a central role in this interac-
tion, as GSK3b is a negative regulator of b-catenin but
positively regulates NF-Bb yt a r g e t i n gI B, the major
inhibitor of NF-B, to proteasomal degradation [65].
Furthermore, b-catenin itself can form a complex with
the p50 subunit of NF-B, thereby preventing NF-B
transcriptional activity [66]. In ECs both pathways play a
major role in angiogenesis, inflammatory response and
vascular homeostasis and although interaction has not
been confirmed so far it is likely that Wnt/b-catenin
and NF-B also interact in the endothelium.
Recent studies link Wnt/b-catenin to hypoxia signal-
ing by the expression of von Hippel Lindau (VHL) via
the b-catenin-TCF-4 complex [67]. VHL is an ubiquitin
ligase involved in degradation of hydroxylated hypoxia
inducible factor-1a (HIF-1a). In turn HIF-1a can
directly bind to b-catenin, competing with TCF-4 and
thereby enhancing hypoxia-mediated transcription [68].
Whether the very same mechanism operates in ECs
remains to be shown. Interestingly, searching for astro-
cytic BBB-maturation factors regulated by oxygen, Lee
and colleagues identified the potential tumor suppressor
src-suppressed C-kinase substrate (SSeCKS, spoken
“essex”, human ortholog is gravin), which was upregu-
lated upon increasing oxygen tension [69]. The overex-
pression of SSeCKS in astrocytes markedly
downregulated VEGF and upregulated Ang-1 expression
in vitro, thereby leading to increased junction localiza-
tion of ZO-1 and claudin-1 in ECs. Furthermore,
SSeCKS can be induced in astrocytes by PDGF-B, which
in turn is produced by endothelial cells and plays also
an important role in pericyte recruitment to blood ves-
sels [70].
It is tempting to speculate that a molecular link
between Wnt and hypoxia signaling may also be rele-
vant for the endothelial cell response in physiological
and pathological sprouting angiogenesis.
Endothelial Wnt pathway in CNS pathologies
Since Wnt signaling was identified to play a major role
in vascular development and differentiation, it is of par-
ticular interest to understand its involvement in patho-
logical angiogenesis in which hypoxia is known to be
one of the major driving forces.
Tissue hypoxia takes also place in tumors and is
described as a prerequisite for the angiogenic switch of
various cancers, leading to the massive expression of
VEGF-A by hypoxic tumor cells [71]. The most frequent
and most malignant primary brain tumors of adulthood
are WHO grade IV astrocytoma (glioblastoma), which
are known to be highly hypoxic and extensively vascu-
larized [72]. Recent reports suggest that b-catenin sig-
naling in glioma cells participates in tumor cell
progression and invasion [73-75]. This effect is, at least
partially, mediated by the epidermal growth factor
receptor (EGFR), which activates ERK leading to the
dissociation of a-a n db-catenin, thereby promoting
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glioblastoma cells express Wnt growth factors, lead-
ing to autocrine and/or paracrine signaling to the
vascular compartment, as it is known from VEGF, is
poorly known.
Nevertheless, glioblastoma tumor vessels were demon-
strated to regularly show nuclear b-catenin in human
samples and in an N-ethyl-N-nitrosourea-induced rat
glioma model [76,77]. The specific function of endothe-
lial b-catenin signaling in glioblastoma however has not
been determined so far.
After stroke, independent of its etiology from ischemic
or hemorrhagic insult, BBB integrity is focally abolished
and during glia scar formation, inflammation and neo-
angiogenesis occurs [78]. Lithium chloride (LiCl), which
is a widely used inhibitor of GSK3b, was frequently
applied to treat bipolar mood disorders. More recently,
LiCl was implicated in the reduction of infarct volume
in a rat model for stroke [79]. After middle cerebral
artery occlusion (MCAO), LiCl had a beneficial effect
on the survival of neurons up to 3 h after onset of
stroke, but the effect on EC has not been determined.
Interestingly, Guo and co-workers have shown that LiCl
upregulates VEGF-A in human brain microvascular ECs
and astrocytes in vitro through PI3K/GSK-3b-dependent
and -independent pathways, respectively [80]. This
might contribute to the beneficial effect of LiCl treat-
ment on vascular remodeling after stroke [81]. VEGF in
turn is a described Wnt/b-catenin target and conse-
quently, b-catenin signaling might have multimodal
effects for the prevention of the destructive effects eli-
cited by stroke. Not to forget the possibility that LiCl
via b-catenin activation, may help to maintain and/or
re-induce barrier properties in brain microvessels of the
infarct area.
Finally, the familial form of Alzheimer’s disease (AD),
in which the presenilin-1 (PSEN1) gene is mutated, has
been correlated with reduced levels of active b-catenin
[82]. And recently, amyloid-beta peptide (Ab), the major
product of the presenilin/g-secretase complex, was
demonstrated to bind to the CRD of Fzd, thereby inhi-
biting Wnt mediated signaling [83]. This may further
correlate with the known BBB defects in AD, which by
now seem to be related to decreased clearance of Ab by
EC-specific transporters (reviewed in [41]). Herein the
b-catenin target gene P-glycoprotein (MDR-1, ABCB1)
appears to play the major role in ECs.
Important clinical insight into the involvement of Wnt
signaling in vascular pathogenesis came from studies of
the human disorders Norrie disease (ND), Coat’s disease
and familial exudative vitreoretinopathy (FEVR) as men-
tioned above [84]. FEVR has been linked to 4 different
loci, EVR-1 to 4, three of which encode for Norrin,
Fzd4 and Lrp5 [46].
Norrie disease is caused by a X-linked recessive muta-
tion of Norrie disease pseudoglioma gene (NDP), coding
for Norrin/Norrie disease protein (Ndp) [85,86]. The
mouse Ndp KO displays a lack of deep retinal capillary
networks and subsequent retinal hypoxia, which is accom-
panied by an increased expression of the angiogenic fac-
tors VEGF-A, b3 integrin and Tie1 [45]. Norrie patients
suffer from blindness of both eyes at birth or soon after,
leukocoria and cateract formation. Additionally, they
develop sensorineural hearing loss, impaired motor skills
and mental retardation caused by vascular defects in the
inner ear and the cerebellum (reviewed in [87]).
In contrast to NDP mutation, Fzd4 mutations are
autosomal dominant and those of Lrp5 are autosomal
recessive, but phenotypes are largely overlapping.
With the identification of TSPAN12 as a modulator of
Norrin signaling that genetically and functionally inter-
acts with Fzd4, another gene could potentially be
mutated in the FEVR family of diseases, although no
mutation has been discovered in humans so far [52].
Conclusions
The underlying mechanisms for CNS vascularization in
general and for endothelial barrier differentiation in par-
ticular have been obscure for about one century, since
Paul Ehrlich and Edwin Goldmann established the con-
cept of the BBB. The recent identification of the Wnt/b-
catenin pathway as a driving force for brain angiogenesis
and BBB differentiation has shed first light onto this
burning question. Although Wnt7a/7b were confirmed
to be the major ligands activating b-catenin signaling in
brain and spinal cord ECs, it remains elusive if exactly
the same molecular pathway operates in the entire CNS
to induce the BBB phenotype in ECs. This hypothesis is
challenged in the retina, in which Norrin via Fzd4-Lrp5-
TSPAN12 appears to be the predominant activator of b-
catenin signaling in ECs. The finding that ECs can
express the majority of Wnt pathway related genes in
vitro and/or in vivo makes the interpretation of signal
specificity even more complicated.
Furthermore, Wnt signals in the brain vasculature will
integrate with other pathways such as Notch, FGF, TGFb
and Sonic hedgehog to regulate BBB formation. The chal-
lenges for the further understanding of brain angiogenesis
and endothelial barrier differentiation are the identification
of cell and tissue specificity of the Wnt pathway for CNS
vascular physiology, as well as the definition of Wnt sig-
naling as a bona fide target to modulate barrier properties
under pathological conditions.
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